Assuntos
Orçamentos , Humanos , Saúde Global , Cirurgia Geral , Procedimentos Cirúrgicos Operatórios/economia , IdiomaAssuntos
Minorias Étnicas e Raciais , Confiança , Hesitação Vacinal , Humanos , Hesitação Vacinal/psicologia , Hesitação Vacinal/estatística & dados numéricos , Disparidades em Assistência à Saúde , Vacinação/psicologia , Vacinação/estatística & dados numéricos , Disparidades nos Níveis de Saúde , Etnicidade/psicologiaRESUMO
OBJECTIVES: COVID-19 immunization has been shown to be effective in the prevention of COVID-19. Traditionally, two doses of COVID-19 vaccines are required. Booster immunization is generally required when immunity has deteriorated. METHODS: The effectiveness of the alternate boost immunization protocol is still unknown. The authors of this study used a cost-effectiveness analysis, which is a retrospective analysis on datasets on cost and effectiveness, to examine the projected cost-effectiveness of boosting COVID-19 vaccination by a fourth dose. RESULTS: The cost-effectiveness of the fourth-dose COVID booster vaccine was found to be higher in this study. CONCLUSION: It could imply that vaccinating against the current pandemic of the novel form, omicron, with the additional COVID-19 vaccine is a smarter idea.
Assuntos
Síndrome de Brugada , Vacinas contra COVID-19 , COVID-19 , Síndrome de Brugada/diagnóstico , Síndrome de Brugada/epidemiologia , Síndrome de Brugada/terapia , COVID-19/prevenção & controle , Vacinas contra COVID-19/efeitos adversos , Eletrocardiografia , Febre/complicações , Humanos , Incidência , Vacinação/efeitos adversosRESUMO
COVID-19 immunization has been shown to be effective in the prevention of COVID-19. Traditionally, two vaccination doses given by intramuscular injection are required. Many scientists present ideas for an alternative administration of COVID-19 for reducing the cost and solving the problem of insufficient COVID-19 vaccine supply. Regarding the new alternative vaccine administration, the important consideration is on cost, utility and safety. Herein, we performed cost-utility-safety analysis of alternative intradermal versus classical intramuscular COVID-19 vaccination. From cost analysis, a 80% cost reduction was derived from using intradermal COVID-19 vaccine administration comparing to intramuscular vaccination. Additional, cost-utility and cost-safety analysis also show that the cost per utility and cost per safety values for intradermal vaccination are lower than those of intramuscular vaccination. According to current research, intradermal immunization is a viable alternative to traditional intramuscular COVID-19 vaccine and may even be superior.